NCT00274976已完成2 期
Subcutaneous Campath-1H in Fludarabine-Refractory CLL
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 70
- 主要终点
- Safety and efficacy
研究概览
简要总结
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.
PURPOSE: This phase II trial is studying how well giving alemtuzumab by injection works in treating patients with advanced chronic lymphocytic leukemia that did not respond to previous fludarabine.
详细描述
OBJECTIVES:
- Compare the safety and efficacy of subcutaneous alemtuzumab vs intravenous alemtuzumab in patients with fludarabine-refractory advanced chronic lymphocytic leukemia.
- Determine the response in patients with high-risk genetic abnormalities (unmutated immunoglobulin variable heavy-chain [IgVH] status, del [17p], del [11q]) treated with subcutaneous alemtuzumab after progression on fludarabine.
OUTLINE: This is a multicenter study.
Patients receive alemtuzumab IV once, followed 1 week later by alemtuzumab subcutaneously once weekly for up to 12 weeks.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Safety and efficacy
Response
次要结局
未报告次要终点
研究者
研究点 (70)
Loading locations...
相似试验
已完成
1 期
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT00634881German CLL Study Group13
已完成
2 期
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic DisordersCongenital Amegakaryocytic ThrombocytopeniaDiamond-blackfan AnemiaLeukemiaMyelodysplastic SyndromesSevere Congenital NeutropeniaNCT00301834University of California, San Francisco35
已完成
2 期
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLLLeukemiaNCT00858117Northwestern University30
Unknown
1 期
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's LymphomaLymphomaNCT00363090Toronto Sunnybrook Regional Cancer Centre84
已完成
2 期
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic LeukemiaLeukemiaNCT00436904Mayo Clinic30